Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Palbociclib Combinations in HR+/HER2- Metastatic Breast Cancer Patients: A Non-Interventional Prospective Study on the Treatment Patterns & Clinical Outcomes in Africa Middle East (PRECIOUS)

NCT04937660 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04937660
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04937660 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Palbociclib Combinations in HR+/HER2- Metastatic Breast Cancer Patients: A Non-Interventional Prospective Study on the Treatment Patterns & Clinical Outcomes in Africa Middle East (PRECIOUS)
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
July 15, 2021
Completion date
April 29, 2025
Enrollment
185 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer